NDA 219122 · Azurity
Brynovin
Sitagliptin Hydrochloride · Oral · Dipeptidyl Peptidase 4 Inhibitor
DiscontinuedLast checked: Nov 20, 2026Latest source record: Jan 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jan 16, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
511
155 Phase 3, 14 recruiting
FAERS reports
1
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 2, 2025.
BRYNOVIN is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use BRYNOVIN is not recommended in patients with type 1 diabetes. BRYNOVIN has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using BRYNOVIN. [see Warnings and Precautions ( 5.1 )] . BRYNOVIN is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: • BRYNOVIN is not recommended in patients with type 1 diabetes. ( 1 ) • BRYNOVIN has not been studied in patients with a history of pancreatitis. ( 1 )
Mechanism: Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes mellitus by slowing the inactivation of incretin hormones. Concentrations of the active intact hormones are increased by sitagliptin, thereby increasing and prolonging the action of these hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 16, 2025 Original approval · Type 3 - New Dosage Form LabelMedication GuideLetter
1 products under this application
- BRYNOVIN · SITAGLIPTIN HYDROCHLORIDE EQ 25MG BASE/ML · SOLUTION, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Sitagliptin" as an intervention, any sponsor and status, largest first.
- Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00790205 · 14,671 participants · Start Dec 10, 2008 · Primary completion Mar 30, 2015
Drug: Sitagliptin; Placebo · For: Type 2 Diabetes Mellitus
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 DiabetesPivotal-lookingCompleted
GRADE Study GroupAcademic, hospital or other
NCT01794143 · 7,850 participants · Start May 2013 · Primary completion Apr 30, 2021
Drug: Sulfonylurea (glimepiride); DPP-4 inhibitor (sitagliptin) and 2 more · For: Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications
Sites: Birmingham, Alabama; Phoenix, Arizona; San Diego, California · 36 sites in all
- A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01709305 · 5,570 participants · Start Nov 8, 2012 · Primary completion Apr 17, 2015
Drug: Metformin; Sitagliptin and 4 more · For: Type 2 Diabetes Mellitus
- Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 DiabetesPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01289990 · 2,705 participants · Start Feb 2011 · Primary completion May 2013
Drug: BI 10773; Placebo and 28 more · For: Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Glendale, Arizona; Mesa, Arizona · 243 sites in all
- Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 DiabetesPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00860288 · 1,988 participants · Start Feb 2009 · Primary completion Mar 2011
Drug: Vildagliptin; Metformin and 2 more · For: Diabetes Mellitus, Type 2
Sites: Buenos Aires, Argentina; Rosario, Argentina; Graz, Austria · 187 sites in all
- Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT02607865 · 1,864 participants · Start Feb 15, 2016 · Primary completion Feb 14, 2017
Drug: semaglutide; sitagliptin and 1 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Anniston, Alabama; Birmingham, Alabama; Tuscumbia, Alabama · 242 sites in all
- MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00722371 · 1,615 participants · Start Sep 5, 2008 · Primary completion Oct 26, 2010
Drug: Sitagliptin phosphate; Pioglitazone hydrochloride and 3 more · For: Type 2 Diabetes Mellitus
- Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00545584 · 1,512 participants · Start Apr 1, 2007 · Primary completion Nov 19, 2009
Drug: sitagliptin phosphate · For: Diabetes Mellitus, Non-Insulin-Dependent
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- adverse event1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.
Silver HJ, Olson D, Mayfield D, et al. · Diabetes Obes Metab 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
Nathan DM, Lachin JM, Balasubramanyam A, et al. · N Engl J Med 2022 · Comparative Study, Randomized Controlled Trial
- Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
Nathan DM, Lachin JM, Bebu I, et al. · N Engl J Med 2022 · Comparative Study, Randomized Controlled Trial
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Green JB, Bethel MA, Armstrong PW, et al. · N Engl J Med 2015 · Comparative Study, Multicenter Study
- Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.
Ji L, Dong X, Li Y, et al. · Diabetes Obes Metab 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
Rosenstock J, Allison D, Birkenfeld AL, et al. · JAMA 2019 · Clinical Trial, Phase III, Comparative Study
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.